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Objectives: Pancreatic cancer has a relatively low incidence but ranks fourth among 
  cancer-related deaths in western countries. In Denmark, cancer survival generally is lower than 
in other countries with comparable health care systems. As a result, in 2000, a national strategy 
to improve cancer survival was introduced. Here we examine time trends in survival and relative 
mortality among pancreatic cancer patients, using Danish population and medical databases.
Methods: Using the Danish National Patient Registry (DNPR), we identified all incident pan-
creatic cancer patients (n = 2968) diagnosed between 1998 and 2009 in the Central and North 
Denmark Regions. We computed the 1-, 3-, and 5-year survival and relative mortality (MRR) 
and associated 95% confidence intervals (CI) adjusting for age and gender. Among surgical 
patients, we also computed 30-day mortality and 30-day MRR.
Results: Median age at diagnosis was approximately 71 years. The annual number of patients 
increased from 189 in 1998–2000 to 302 in 2007–2009. There was a slight improvement in 1-, 
3-, and 5-year survival over time from 14.8% to 17.7%; 3.5% to a predicted 5.6%; and from 
2.0% to a predicted 3.8%, from 1998–2000 to 2007–2009, respectively. Correspondingly, the 
adjusted relative mortality decreased from 1998–2000 to 2007–2009. Thirty-day post-operative 
mortality decreased from 12.2% in 1998–2000 to 5.8% in 2007–2009, corresponding to a 30-day 
MRR of 0.38, 95% CI = 0.09, 1.6 in 2007–2009.
Conclusion: There was a slight, albeit modest, improvement in survival and relative mortal-
ity in pancreatic cancer patients between 1998 and 2009. As we lacked staging information, 
it is not clear if this improvement is attributable to earlier stage at diagnosis. However, these 
improvements likely reflect the national cancer strategy which aimed to centralize cancer 
services and involved the introduction of palliative and adjuvant chemotherapy for pancreatic 
cancer in Denmark. The dismal prognosis of pancreatic cancer means that efforts to improve 
survival need to be intensified.
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Introduction
Pancreatic cancer is a rapidly progressing disease with a dismal prognosis. It ranks as 
the fourth leading cause of cancer-related death in developed countries.1 In 2008 alone, 
the standardized incidence rate (standardized to a world standard) of pancreatic cancer 
worldwide was 3.9 per 100,000 persons while the standardized (world standard) mortal-
ity rate was only slightly lower at 3.7 per 100,000 persons.1 In Denmark, the incidence 
rate was 15 and 17 per 100,000 women and men, respectively,2 and that of mortality was 
14.4 and 16.2 per 100,000, respectively (standardized to the Danish population 2000).3 
The disease has an insidious onset with relatively nonspecific symptoms.4 As a result, 
the majority of patients are diagnosed at an advanced stage,5–7 limiting the possibility of Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
20
Cronin-Fenton et al
  curative treatment.8 Surgery remains the only curative   treatment 
for pancreatic cancer.9 However, research indicates that less 
than 20% of patients are suitable surgical candidates.8
In the US, survival from most cancers has significantly 
improved between 1950 and 1995,10 likely facilitated by tech-
nological advances enabling earlier cancer detection and more 
effective cancer-directed treatments.11 However, survival 
from pancreatic cancer between 1950 and 1995 increased 
by only 3%, contrasting with the improvements observed 
for several other cancers.10 Research in the Nordic countries 
has also indicated little change in pancreatic cancer survival 
between 1964 and 2006, and lowest survival among Danish 
patients.5,12 In 2000, the Danish government initiated the 
“National Cancer Plan I ”, with an update in 2005. The aims 
of the plan include enhancing cancer prevention; improving 
and accelerating the patient referral pathway; strengthening 
cancer surgery; monitoring cancer care; and implementing 
a multidisciplinary approach to diagnosis and treatment.13 
It is critical to regularly monitor cancer patient survival to 
evaluate the effect of this cancer plan. In the current study 
therefore, we examined trends in mortality and survival of 
pancreatic cancer patients over time using Danish population 
and medical databases.
Material and methods
We conducted this study in the Central and the North Denmark 
Regions, with a combined population of 1.8 million persons, 
representing approximately one-third of the Danish population. 
The National Health Service provides tax-supported health 
care for all inhabitants of Denmark, guaranteeing free access to 
hospitals. Virtually no pancreatic cancer patients were treated 
in private hospitals during the study period.
We used the Danish National Patient Registry (DNPR) to 
identify the pancreatic cancer patients included in the current 
study. The DNPR contains information on all admissions from 
nonpsychiatric hospitals in Denmark since 1977,14 and outpa-
tient and emergency room visits at these hospitals since 1995. 
The DNPR includes information on civil personal registration 
(CPR) number, dates of admission and discharge, surgical 
procedure(s) performed, and up to 20 diagnoses from each 
hospital contact. Diagnoses have been classified according to 
the International Classification of Diseases (ICD) 8th edition 
until the end of 1993 and 10th edition thereafter.
Identification of pancreatic cancer 
patients
We identified all patients who had an incident diagnosis of 
pancreatic cancer between January 1, 1998 and December 31, 
2009 using the DNPR. We included all patients with an 
ICD-10 code of C25.x.
Identification of pancreatic cancer 
surgery
Surgical procedures have been classified according to a Dan-
ish classification system until the end of 1995 and according 
to a Danish version of the Nordic Classification of Surgi-
cal Procedures (NCSP) thereafter. We used the DNPR to 
identify the surgical procedures pancreatectomy (JLC.20), 
pancreatoduodenectomy (JLC.30), and total pancreatoduo-
denectomy (JLC.40) conducted within 90 days after the 
pancreatic cancer diagnosis.
Survival
Since 1968 the Danish Civil Registration System (DCRS) 
has assigned a unique 10-digit civil personal registration 
(CPR) number to all Danish citizens.15 This number, unique 
to each Danish resident, is used in all Danish registries, 
allowing unambiguous individual-level data linkage. From 
the DCRS we also obtained information on vital status 
(dead or alive), date of death, and residence for all cancer 
patients.
Statistical analysis
We followed each patient from the date of pancreatic cancer 
diagnosis until emigration, death, or 25 June 2010, whichever 
came first. We constructed Kaplan–Meier survival curves 
to illustrate crude survival stratified by diagnostic period 
(1998–2000, 2001–2003, 2004–2006, and 2007–2009). In the 
most recent periods we estimated 1-, 3-, and 5-year survival 
using a hybrid analysis whereby survival was estimated using 
the survival experience of patients in the previous periods.16 We 
compared mortality over time using Cox proportional hazards 
regression analysis with 1998–2000 as the reference period to 
estimate 1-, 3- and 5-year mortality rate ratios (MRRs) and 
associated 95% confidence intervals (CIs) adjusting for age 
group (15–59 years, 60–79 years, $80 years), and gender.
Among patients who underwent surgery, we computed 
30-day mortality rates from date of surgery for the four 
time periods. We used Cox proportional hazards regression 
analysis and estimated 30-day MRRs and associated 95% 
CIs with 1998–2000 as the reference period, adjusting for 
age group and gender. We used the Cochran–Armitage trend 
test to evaluate the trend in 30-day mortality rates from 1998 
through 2009.17
All analyses were performed using SAS version 9.2 (SAS 
Institute Inc., Cary, NC).Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Results
A total of 2968 patients was diagnosed with pancreatic cancer 
between 1998 and 2009 in the Central and North Denmark 
regions. The number of pancreatic cancer patients increased 
over the study period from 607 in 1998–2000 to 702 in 
2001–2003, 768 patients in 2004–2006, and 891 patients 
in 2007–2009. Median age at diagnosis was 71 years and 
varied little by period of diagnosis (Table 1). Women were, 
on average, older at diagnosis than men and accounted for 
51% of pancreatic cancer cases (Figure 1).
Figure 2 illustrates the survival curve of pancreatic cancer 
patients by period of diagnosis. Regardless of diagnostic 
period, less than 50% of patients were alive at 6 months 
after diagnosis. Median survival was 2.7 months for patients 
diagnosed in 1998–2000; 2.8 months for patients diagnosed 
in 2001–2003; 3.2 months for those diagnosed in 2004–2006 
and 2007–2009. Table 1 also outlines the cumulative propor-
tion of patients surviving at 1, 3, and 5 years, as well as the 
crude and adjusted MRRs by diagnostic period, using patients 
diagnosed in the earliest period (1998–2000) as a reference 
group. Patients diagnosed in 2004–2006 and 2007–2009 had 
slightly better survival 1-year post-diagnosis than those in the 
earlier periods (17.4%, 95% CI = 14.9%, 20.2%, and 17.7%, 
95% CI = 15.3%, 20.4%, versus 14.8%, 95% CI = 12.1%, 
17.8% and 15.1, 95% CI = 12.6%, 17.9%, respectively). The 
projected estimates for 3- and 5-year survival also increased 
from 3.5% (95% CI = 2.2%, 5.1%) to 5.6% (95% CI = 4.2%, 
7.4%) and from 2.0% (95% CI = 1.1%, 3.3%) to 3.8% (95% 
CI = 2.6%, 5.4%), respectively, over the study period.
Table 2 outlines the cumulative survival at 1, 3, and 
5 years stratified by age and gender. One-year survival 
appeared to be best in the youngest age group, ranging from 
19.7% (95% CI = 11.2%, 30.0%) to 27.5% (95% CI = 16.4%, 
19.9%) in women. One-year survival was lower in women 
aged 60–79 years (range 13.1%, 95% CI = 8.8%, 18.1%, to 
17.9%, 95% CI = 13.1%, 23.3%), and was lowest in elderly 
patients (age 80+) – range 8.2%, 95% CI = 3.8%, 14.6% to 
10%, 95% CI = 4.7%, 17.7%). There was little change in 
3- and 5-year survival estimates from 1998 through 2009. 
The same pattern was evident among male pancreatic cancer 
patients, where the cumulative proportion of men surviv-
ing 1-year after diagnosis was highest in the youngest age 
group, lower in the middle age group and lowest in the 
elderly patients.
A total of 176 pancreatic cancer patients was surgically 
treated within 90 days after diagnosis, accounting for a mere 
5.9% of the total patient population. The median age of 
surgical patients was lower than that of nonsurgical patients 
(surgical patients median age 62.4 compared with a median 
age of 71.8 in nonsurgical patients). Surgical patients were 
slightly older in the latter two diagnostic periods than those 
diagnosed between 1998 and 2003. The 30-day mortality 
after surgery was approximately halved after the first period 
1998–2001 from 12.2% to 6.8%, 5.1% and 5.8%, correspond-
ing to an age-adjusted MRR of 0.38 (95% CI = 0.09, 1.6) 
in the last period compared with the first period (Table 3) 
(2-sided P-value = 0.26).
Discussion
This study shows that survival of pancreatic cancer patients 
in Denmark marginally improved between 1998 and 2009. 
Although only a modest improvement, pancreatic cancer 
Table 1 Cumulative survival and crude and adjusted relative mortality (MRR) (and associated 95% confidence intervals) for pancreatic 
cancer patients diagnosed in Central and northern Denmark, 1998–2009
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 607 702 768 891
Median age (years) 72 71 71 71
1-year
Survival 14.8% (12.1%–17.8%) 15.1% (12.6%–17.9%) 17.4% (14.9%–20.2%) 17.7% (15.3%–20.4%)
relative mortality 1 (reference) 0.98 (0.87–1.10) 0.88 (0.78–0.99) 0.88 (0.79–0.99)
Adjusted relative mortalitya 1 (reference) 0.98 (0.87–1.11) 0.87 (0.77–0.98) 0.86 (0.77–0.96)
3-year
Survival 3.5% (2.2%–5.1%) 3.6% (2.4%–5.1%) 5.1% (3.7%–6.8%) 5.6% (4.2%–7.4%)b
relative mortality 1 (reference) 0.98 (0.87–1.09) 0.87 (0.78–0.97) 0.87 (0.78–0.96)b
Adjusted relative mortalitya 1 (reference) 0.97 (0.87–1.09) 0.86 (0.77–0.96) 0.84 (0.75–0.93)b
5-year
Survival 2.0% (1.1%–3.3%) 2.1% (1.3%–3.4%) 3.4% (2.3%–4.9%)b 3.8% (2.6%–5.4%)b
relative mortality 1 (reference) 0.98 (0.88–1.09) 0.87 (0.78–0.97)b 0.86 (0.78–0.96)b
Adjusted relative mortalitya 1 (reference) 0.97 (0.87–1.08) 0.85 (0.76–0.95)b 0.83 (0.75–0.92)b
Notes: aAdjusted for age and gender; bPredicted values.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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has such a low median survival, that any improvement is 
  noteworthy. There was also a decline in 30-day mortality after 
surgery for pancreatic cancer, likely attributable to increas-
ing centralization of cancer services and a multidisciplinary 
approach to cancer treatment.18
When interpreting our findings several factors should be 
considered. The large size and uniformly organized health 
care system facilitated a population-based design with 
accurate survival estimates, and reduced selection bias. The 
use of the DCRS ensured complete follow-up.15 We used 
the DNPR rather than the Danish Cancer Registry to obtain 
information on individuals with pancreatic cancer due to 
the delay in reporting of cancer cases to the cancer registry. 
As the DNPR is continuously updated, it provided an ideal 
setting in which to monitor any recent changes in survival. 
Furthermore, the sensitivity and positive predictive value of 
a cancer diagnosis in the DNPR is high, increasing the valid-
ity of our study.14,19,20 Presentation of estimates of survival 
and mortality make the findings from this study suitable for 
comparison with findings from other countries. Our study 
also serves to highlight that data from patient registries are 
suitable tools to use when monitoring cancer survival.
Improvements in pancreatic cancer survival could be 
facilitated by detecting the cancer before local invasion or 
distant metastatic disease is established – when surgery is 
most effective. An increase in the proportion of patients 
with localized disease would also improve the selection of 
surgical candidates, thereby improving surgical outcomes. 
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Figure 2 Kaplan–Meier survival curves for patients with pancreatic cancer in Central and northern Denmark regions, 1998–2009.
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The National Cancer Strategy may have contributed to the 
detection and diagnosis of pancreatic cancer at an earlier 
stage. Unfortunately, we had no information on clinical 
characteristics such as cancer stage at diagnosis and cancer-
directed treatment, other than cancer surgery. Therefore, 
we were unable to investigate the impact of these factors 
on pancreatic cancer survival and how possible changes in 
these factors may correlate with the observed changes in 
survival.
Although pancreatic cancer is frequently resistant to che-
motherapy, randomized trials have shown that chemotherapy 
can be beneficial in selected groups of patients, particularly 
those who undergo surgical resection.21 The majority of 
pancreatic cancer patients are elderly when diagnosed, and 
therefore may be considered unlikely to respond to treatment 
or unable to tolerate aggressive cancer-directed treatments.
Pancreatectomy is considered a complex and technically 
challenging procedure due to the location and inacces-
sibility of the pancreas.22 Research suggests the procedure 
is underutilized in clinical practice.23 The proportion of 
patients undergoing pancreatectomy in the current study 
was similar to rates observed in Ireland (7%)24 and Scotland 
(5%),25 but much lower than rates in Sweden (15%),26 the 
Netherlands (11%),27 and the US (∼15%)28,29 over comparable 
Table 2A Cumulative survival (and associated 95% confidence intervals) for male pancreatic cancer patients diagnosed in Central and 
northern Denmark, 1998–2009
Men Year of diagnosis
age (years) 1998–2000 2001–2003 2004–2006 2007–2009
15–59
number of cancer patients 78 82 86 82
1-year survival 24.4% (15.5%–34.3%) 18.3% (10.8%–27.3%) 30.2% (20.9%–40.1%) 24.0% (15.3%–33.7%)
3-year survival 9.0% (3.9%–16.6%) 7.3% (3.0%–14.3%) 10.5% (5.1%–18.0%) 7.7% (3.3%–14.4%)a
5-year survival 7.7% (3.1%–14.9%) 6.1% (2.3%–12.7%) 8.3% (3.7%–15.2%)a 6.1% (2.4%–12.1%)a
60–79
number of cancer patients 170 225 249 277
1-year survival 11.2% (7.0%–16.4%) 18.2% (13.5%–23.5%) 17.3% (12.9%–22.2%) 20.5% (15.9%–25.6%)
3-year survival 1.8% (0.5%–4.7%) 2.7% (1.1%–5.4%) 5.6% (3.2%–9.0%) 7.0% (4.2%–10.7%)a
5-year survival 0.6% (0.1%–3.0%) 0.4% (0.0%–2.3%) 3.3% (1.5%–6.2%)a 4.1% (1.9%–7.6%)a
80+
number of cancer patients 45 50 60 63
1-year survival 8.9% (2.8%–19.3%) 6.0% (1.6%–14.9%) 8.3% (3.1%–17.0%) 14.3% (7.0%–24.0%)
3-year survival 0% 0% 3.3% (0.6%–10.2%) 3.5% (0.7%–10.3%)a
5-year survival 0% 0% – –
Note: aPredicted values.
Table 2B Cumulative survival (and associated 95% confidence intervals) for female pancreatic cancer patients diagnosed in Central 
and northern Denmark, 1998–2009
Women Year of diagnosis
age (years) 1998–2000 2001–2003 2004–2006 2007–2009
15–59
number of cancer patients 63 66 57 57
1-year survival 25.4% (15.5%–36.6%) 19.7% (11.2%–30.0%) 22.8% (13.0%–34.3%) 27.5% (16.4%–39.9%)
3-year survival 7.9% (2.9%–16.2%) 4.5% (1.2%–11.5%) 10.5% (4.3%–20.0%) 8.2% (2.1%–20.0%)a
5-year survival 6.3% (2.0%–14.2%) – 8.8% (3.3%–17.9%)a 6.6% (1.5%–17.2%)a
60–79
number of cancer patients 170 199 218 276
1-year survival 14.1% (9.4%–19.8%) 13.1% (8.8%–18.1%) 17.9% (13.1%–23.3%) 16.4% (12.2%–21.1%)
3-year survival 2.9% (1.1%–6.3%) 3.5% (1.6%–6.8%) 3.2% (1.4%–6.2%) 6.2% (3.6%–9.7%)a
5-year survival 0% 3.0% (1.2%–6.1%) 1.8% (0.6%–4.3%)a 3.6% (1.5%–7.3%)a
80+
number of cancer patients 81 80 98 136
1-year survival 9.9% (4.6%–17.5%) 10.0% (4.7%–17.7%) 8.2% (3.8%–14.6%) 8.6% (4.6%–14.1%)
3-year survival 1.2% (0.1%–6.0%) 3.8% (1.0%–9.6%) 1.0% (0.1%–5.0%) 0.9% (0.1%–4.3%)a
5-year survival – 0% – –
Note: aPredicted values.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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  diagnostic periods. Reasons for such variation in surgical 
rates are not clear. We incorporated information on surgery 
within 90 days of diagnosis; the US study incorporated sur-
gery within 120 days; and the Irish study, based on cancer 
registry data, included surgeries registered within the first 
year after diagnosis. These differences may account for the 
variation in surgical rates across these countries, however 
given the poor survival of pancreatic cancer; it is likely that 
surgery with a curative intent would be given soon after 
diagnosis. The difference in surgical rates may also be due 
to the fact that patients with localized stage are considered 
the only potentially curable patients, and international 
studies have shown a more advanced stage distribution 
among Danish cancer patients, generally, than in other 
developed countries with comparable health care systems.30 
Nonetheless, despite the relatively low uptake of surgery, in 
these Danish pancreatic cancer patients we saw a decrease 
in postoperative mortality consistent with trends reported in 
the Nordic countries5 and elsewhere.31–33 This lower mortality 
may reflect the implementation of the National Cancer Plan, 
specifically strengthening and centralization of surgery, and 
a more multidisciplinary approach to cancer treatment.18
Furthermore, the National Cancer Plan also aims to 
improve cancer diagnostics through increasing the availabil-
ity of cancer scanners, for example. This may have created 
a “lead-time bias” in the current study, whereby patients are 
diagnosed at an earlier stage and so their survival appears 
longer. Unfortunately, we did not have information on 
cancer stage and so we are unable to explore this possibility 
further.
Smoking is one of the few established risk factors for 
pancreatic cancer, others being type 2 diabetes and chronic 
pancreatitis.34 It has been estimated that smoking prevention 
could decrease the incidence of pancreatic cancer by as much 
as 20%.6 Due to the poor prognosis of the disease, cancer 
prevention may be the only way to reduce the disease bur-
den in the population. However, the relatively occult nature 
of pancreatic cancer etiology means that population-based 
  survival and relative mortality, such as presented in the 
  current study, are likely to remain key indicators of progress 
against this deadly disease.
In conclusion, this study shows a very slight improvement 
in pancreatic cancer survival and decreased relative mortality. 
These findings are consistent with findings for the Danish 
cancer patient population generally,5,12 and are likely to be a 
direct effect of the dissemination of the National Cancer Plan. 
However, the poor prognosis of this disease means that efforts 
at preventing, diagnosing and treating this disease need to be 
intensified in order to continue to improve survival.
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